CSIMarket
 

Lyra Therapeutics Inc   (LYRA)
Other Ticker:  
 

Lyra Therapeutics Inc 's Working Capital Per Sales

LYRA's Working Capital and Revenue growth



LYRA Working Capital Per Revenue (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Working Capital Change -13.12 % 0.71 % 280.02 % 191.05 % 128.76 %
Y / Y Revenue Change 51.53 % -12.76 % -12.39 % -95.94 % 2464.29 %
Working Capital Per Revenue 62.41 74.35 70.38 57.84 39.84
Total Ranking # 2879 # 3235 # 3182 # 2360 # 2163
Seq. Working Capital Change -23.88 % 59.34 % -18.2 % -12.44 % -11.76 %
Seq. Revenue Change 18.78 % 11.71 % 3627.27 % -96.94 % -31.62 %





Comment on LYRA's Working Capital Per Revenue in the third quarter 2023
Lyra Therapeutics Inc 's Working Capital Per Revenue in the Q3 2023 sequentially fell to 62.41 but remained above Lyra Therapeutics Inc 's average.

Within Healthcare sector 267 other companies have achieved lower Working Capital Per Revenue during the Q3 2023. While Lyra Therapeutics Inc Working Capital Per Revenue overall ranking has impoved so far in the Q3 2023 to 2879, from total ranking in the second quarter 2023 at 3235.
Working Capital Per Revenue Ranking
Within: No.
Industry # 95
Sector # 268
S&P 500 # 2879


Working Capital Per Revenue Statistics
High Average Low
72.65
56.9
39.74
(Jun 30 2023)   (Jun 30 2022)



Financial Statements
Lyra Therapeutics Inc 's Working Capital $ 86 Millions Visit LYRA's Balance sheet
Lyra Therapeutics Inc 's Revenues $ 1 Millions Visit LYRA's Income Statement
Where are LYRA's Sales coming from? Visit LYRA's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Sep 30 2023, within Healthcare Sector Working Capital Per Revenue
Sera Prognostics Inc   164.50 
Pluri Inc   150.48 
Aim Immunotech Inc   142.13 
Onconova Therapeutics inc   110.28 
Shattuck Labs Inc   98.24 
Bioxcel Therapeutics Inc   96.88 
Fulcrum Therapeutics Inc   95.05 
Sage Therapeutics Inc   90.85 
Akili Inc   87.71 
Singular Genomics Systems Inc   86.26 
Fusion Pharmaceuticals Inc   84.21 
Century Therapeutics inc   81.75 
Cytokinetics Incorporated  74.24 
Oncternal Therapeutics Inc   73.83 
Crinetics Pharmaceuticals Inc   73.35 
Synlogic Inc   66.68 
Verve Therapeutics Inc   62.81 
Inhibikase Therapeutics Inc   61.48 
Lyra Therapeutics Inc   60.93 
Vivos Inc  59.71 
Celldex Therapeutics inc   59.61 
Avidity Biosciences Inc   53.67 
Talis Biomedical Corporation  45.40 
Bridgebio Pharma Inc   44.76 
Astrotech Corp  38.12 
Janux Therapeutics Inc   37.01 
Omega Therapeutics Inc   36.33 
Clene Inc   35.55 
Relay Therapeutics Inc   33.63 
Lumos Pharma Inc   30.84 
Date modified: 2023-11-08T18:33:04+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com